[Mindray Announces Second Quarter 2012 Financial Results Shenzhen, China August 6, 2012 Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the second quarter ended June 30, 2012. Highlights for Second Quarter 2012 Net revenues were $267.8 million, an increase of 23.3%]
[Mindray Announces Second Quarter 2012 Financial Results Shenzhen, China August 6, 2012 Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the second quarter ended June 30, 2012. Highlights for Second Quarter 2012 Net revenues were $267.8 million, an increase of 23.3%]
[Mindray Announces Second Quarter 2012 Financial Results STYLE="font-family:Times New Roman" SIZE="2"> Shenzhen, China August6, 2012 Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the second quarter ended June30, 2012. Highlights for Second Quarter 2012 Net revenues were $267.8 million,]
[Mindray Announces Second Quarter 2012 Financial Results STYLE="font-family:Times New Roman" SIZE="2"> Shenzhen, China August6, 2012 Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the second quarter ended June30, 2012. Highlights for Second Quarter 2012 Net revenues were $267.8 million,]
[Mindray Announces Second Quarter 2012 Financial Results Shenzhen, China August6, 2012 Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the second quarter ended June30, 2012. Highlights for Second Quarter 2012 Net revenues were $267.8 million, anrease of 23.3% over]
[July 27, 2012 Mr. Martin James Senior Assistant Chief Accountant Division of Corporation Finance 100 F Street, NE Re: Mindray Medical International Limited Form 20-F for the Fiscal Year Ended December 31, 2011 Filed April 30, 2012 File No. 001-33036 Dear Mr. James: Company Mindray Comment Letter 2011 Form 20-F Commission On behalf of Mindray Medical International Limited (the ]
[July 27, 2012 Mr. Martin James Senior Assistant Chief Accountant Division of Corporation Finance 100 F Street, NE Re: Mindray Medical International Limited Form 20-F for the Fiscal Year Ended December 31, 2011 Filed April 30, 2012 File No. 001-33036 Dear Mr. James: Company Mindray Comment Letter 2011 Form 20-F Commission On behalf of Mindray Medical International Limited (the ]
[July27, 2012 Mr.Martin James Seniorsistant Chief Accountant Division ofrporation Finance 100 F Street, NE Re: Mindray Medical International Limited Form 20-F for the Fiscal Year Ended December31, 2011 STYLE="font-family:Times New Roman" SIZE="2"> Filed April30, 2012 File No.001-33036 STYLE="font-family:Times New Roman" SIZE="2"> Dear Mr.James:mpany Mindraymment Letter 2011 Form20-F]
[July27, 2012 Mr.Martin James Seniorsistant Chief Accountant Division ofrporation Finance 100 F Street, NE Re: Mindray Medical International Limited Form 20-F for the Fiscal Year Ended December31, 2011 STYLE="font-family:Times New Roman" SIZE="2"> Filed April30, 2012 File No.001-33036 STYLE="font-family:Times New Roman" SIZE="2"> Dear Mr.James:mpany Mindraymment Letter 2011 Form20-F]
[Confidential Treatment Requested By Mindray Medical International Limited In accordance with Rule 83, this letter hasso been clearly marked with the legendnfidential Treatment Requested by Mindray Medical International Limited and each page is marked for the record with the identifying numbers andde M-1 through M-14. Mindray responds to themment Letter follows:]
